Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

NCT02167854 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: BYL719
DRUG: LJM716
DRUG: TRASTUZUMAB

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]